Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.74 | N/A | -35.28% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.74 | N/A | -35.28% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to ongoing development efforts.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline despite the current losses.
Krystal Biotech's earnings report indicates a larger-than-expected loss per share, which contributed to a 6.91% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's financial trajectory. Overall, the results reflect ongoing challenges in achieving profitability as the company continues to invest in its product pipeline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UBIQUITI INC
May 7, 2021